• Je něco špatně v tomto záznamu ?

Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension

S. Aziriova, K. Repova, K. Krajcirovicova, T. Baka, S. Zorad, V. Mojto, P. Slavkovsky, J. Hodosy, M. Adamcova, L. Paulis, F. Simko,

. 2016 ; 67 (6) : 895-902.

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023293

Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff method once a week. The behaviour of rats was investigated during 23-hours in the phenotyper after four weeks of the treatment. Chronic administration of L-NAME induced hypertension without a change in HR. All tested substances partly prevented the increase of SBP, while ivabradine and melatonin also reduced HR. Ivabradine, captopril and melatonin reduced daily food intake, slightly decreased daily water intake and attenuated body weight gain. In L-NAME group, locomotor activity was enhanced by ivabradine, whereas exploratory behaviour was increased by melatonin and captopril. In conclusion, ivabradine, besides its potentially protective hemodynamic actions, does not seem to exert any disturbing effects on behaviour in L-NAME-induced hypertension in rats, while some of its effects were similar to captopril or melatonin. It is suggested that ivabradine used in cardiovascular indications is harmless regarding the effect on behaviour.

000      
00000naa a2200000 a 4500
001      
bmc17023293
003      
CZ-PrNML
005      
20231121090556.0
007      
ta
008      
170720s2016 pl f 000 0|eng||
009      
AR
035    __
$a (PubMed)28195070
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Aziriova, S $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. $7 gn_A_00010713
245    10
$a Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension / $c S. Aziriova, K. Repova, K. Krajcirovicova, T. Baka, S. Zorad, V. Mojto, P. Slavkovsky, J. Hodosy, M. Adamcova, L. Paulis, F. Simko,
520    9_
$a Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff method once a week. The behaviour of rats was investigated during 23-hours in the phenotyper after four weeks of the treatment. Chronic administration of L-NAME induced hypertension without a change in HR. All tested substances partly prevented the increase of SBP, while ivabradine and melatonin also reduced HR. Ivabradine, captopril and melatonin reduced daily food intake, slightly decreased daily water intake and attenuated body weight gain. In L-NAME group, locomotor activity was enhanced by ivabradine, whereas exploratory behaviour was increased by melatonin and captopril. In conclusion, ivabradine, besides its potentially protective hemodynamic actions, does not seem to exert any disturbing effects on behaviour in L-NAME-induced hypertension in rats, while some of its effects were similar to captopril or melatonin. It is suggested that ivabradine used in cardiovascular indications is harmless regarding the effect on behaviour.
650    _2
$a inhibitory ACE $x farmakologie $7 D000806
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x farmakologie $7 D000959
650    _2
$a chování zvířat $x účinky léků $7 D001522
650    _2
$a benzazepiny $x farmakologie $7 D001552
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a kaptopril $x farmakologie $7 D002216
650    _2
$a srdeční frekvence $x účinky léků $7 D006339
650    _2
$a hypertenze $x farmakoterapie $x metabolismus $7 D006973
650    _2
$a lokomoce $x účinky léků $7 D008124
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melatonin $x farmakologie $7 D008550
650    _2
$a NG-nitroargininmethylester $x metabolismus $7 D019331
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a synthasa oxidu dusnatého $x metabolismus $7 D019001
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
655    _2
$a časopisecké články $7 D016428
700    1_
$a Repova, K $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
700    1_
$a Krajcirovicova, K $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
700    1_
$a Baka, T $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
700    1_
$a Zorad, Štefan, $d 1956- $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic. $7 xx0310348
700    1_
$a Mojto, V $u 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
700    1_
$a Slavkovsky, P $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
700    1_
$a Hodosy, J $u Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
700    1_
$a Adamcova, M $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic. $7 gn_A_00001173
700    1_
$a Paulis, L $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovak Republic.
700    1_
$a Simko, F $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. fedor.simko@fmed.uniba.sk. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic. 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
773    0_
$w MED00002908 $t Journal of physiology and pharmacology $x 1899-1505 $g Roč. 67, č. 6 (2016), s. 895-902
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28195070 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20231121090553 $b ABA008
999    __
$a ok $b bmc $g 1238974 $s 984206
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 67 $c 6 $d 895-902 $i 1899-1505 $m Journal of physiology and pharmacology $n J Physiol Pharmacol $x MED00002908
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace